Results 61 to 70 of about 26,674 (238)

Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept [PDF]

, 2016
Background Patients with rheumatoid arthritis (RA), including those treated with biologics, are at increased risk of some vaccine-preventable infections. We evaluated the antibody response to standard 23-valent pneumococcal polysaccharide vaccine (PPSV23)
Alten, Rieke, Bingham, Clifton O., Cohen, Stanley B., Curtis, Jeffrey R., Genovese, Mark C., Kelly, Sheila, Wong, Dennis   +6 more
core   +3 more sources

Conversion From Intravenous In-Hospital Belatacept Injection to Subcutaneous Abatacept Injection in Kidney Transplant Recipients During the First COVID-19 Stay-at-Home Order in France

Transplant International, 2023
The first COVID-19 stay-at-home order came into effect in France on 17 March 2020. Immunocompromised patients were asked to isolate themselves, and outpatient clinic visits were dramatically reduced. In order to avoid visits to the hospital by belatacept-
D. Bertrand, Mélanie Brunel, Ludivine Lebourg, A. Scemla, Mathilde Lemoine, L. Amrouche, C. Laurent, C. Legendre, D. Guerrot, D. Anglicheau, R. Sberro-Soussan   +10 more
semanticscholar   +1 more source

Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study

BMC Rheumatology, 2021
Background Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that causes chronic synovitis, resulting in progressive joint destruction and functional disability and affects approximately 400,000 people in the UK. This real-world study aimed
Ernest Choy, Lara Groves, Daniel Sugrue, Michael Hurst, John Houghton, Srinivasan Venkatachalam, Yusuf I. Patel, James R. Maxwell, Kevin G. Pollock, Sadie Henning   +9 more
doaj   +1 more source

Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales [PDF]

, 2012
Patients in England and Wales with rheumatoid arthritis (RA) receive treatment from the National Health Service (NHS) with therapies approved by the European Medicines Agency (EMA), under guidance from the National Institute for Health and Clinical ...
Andrew J. K. Ostor, Anthony Hammond, Ian N. Bruce, Katharina Sokoll, Marina Anderson, Maya Buch, Michael R. Ehrenstein, Patrick Gordon, Sophia Steer, Yee Chiu   +9 more
core   +2 more sources

Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator‐Initiated, Multicenter, Double‐Blind, Randomized, Placebo‐Controlled Trial

Arthritis & Rheumatology, 2020
T cells play a key role in the pathogenesis of early systemic sclerosis. This study was undertaken to assess the safety and efficacy of abatacept in patients with diffuse cutaneous systemic sclerosis (dcSSc).
D. Khanna, C. Spino, S. Johnson, L. Chung, M. Whitfield, C. Denton, V. Berrocal, Jennifer M. Franks, B. Mehta, J. Molitor, V. Steen, R. Lafyatis, R. Simms, Anna Gill, S. Kafaja, T. Frech, V. Hsu, R. Domsic, J. Pope, J. Gordon, M. Mayes, E. Schiopu, A. Young, N. Sandorfi, Jane Park, F. Hant, E. Bernstein, S. Chatterjee, F. Castelino, A. Ajam, Yue Wang, Tammara A. Wood, Y. Allanore, M. Matucci-Cerinic, O. Distler, Ora Singer, Erica Bush, D. Fox, D. Furst   +38 more
semanticscholar   +1 more source

Abatacept for the prevention of GVHD in patients receiving mismatched unrelated transplants: a real-world analysis

Blood Advances, 2023
Allogeneic hematopoietic cell transplantation (HCT) is paramount to the treatment of relapsed refractory hematologic malignancies. In the absence of a matched related or unrelated donor, a mis-matched unrelated donor (MMUD) increases the donor options ...
S. Raghunandan, Lev Gorfinkel, M. Graiser, Brandi Bratrude, Yvonne Suessmuth, Scott Gillespie, Adrianna L Westbrook, K. Williams, M. Schoettler, L. Kean, J. Horan, A. Langston, M. Qayed, B. Watkins   +13 more
semanticscholar   +1 more source

Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial

Arthritis Research & Therapy, 2018
Background To explore the effect of abatacept treatment on patient-reported outcomes (PROs) in psoriatic arthritis (PsA). Methods Patients with PsA were randomised (1:1) to subcutaneous abatacept 125 mg weekly/placebo for 24 weeks with early escape (EE ...
Vibeke Strand, Evo Alemao, Thomas Lehman, Alyssa Johnsen, Subhashis Banerjee, Harris A. Ahmad, Philip J. Mease   +6 more
doaj   +1 more source

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

Arthritis Care &Research, EarlyView.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; ClinicalTrials.gov identifier ...
Hermine I. Brunner, Jordi Antón, Inmaculada Calvo‐Penadés, Richard Dimelow, Gerd Horneff, Sylvia Kamphuis, Rebecca Marino, Andre van Maurik, Kirsten Minden, Masaaki Mori, Josephine Ocran‐Appiah, Christel Wilkinson, Yuichi Yamasaki, Deepak Assudani, for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) Network investigators   +14 more
wiley   +1 more source

Phase II clinical trial evaluating Abatacept in patients with steroid-refractory chronic graft versus host disease.

Blood, 2023
Steroid-refractory chronic graft versus host disease (cGVHD) remains a significant cause of morbidity and mortality following allogeneic transplantation.
Anita G Koshy, Haesook T. Kim, J. Liegel, J. Arnason, V. Ho, J. Antin, R. Joyce, C. Cutler, Mahasweta Gooptu, S. Nikiforow, Emma K. Logan, P. Elavalakanar, Michele Narcis, D. Stroopinsky, Zachary M Avigan, Leora S Boussi, Susan L Stephenson, Hassan El Banna, P. Bindal, Giulia Cheloni, D. Avigan, R. Soiffer, J. Rosenblatt   +22 more
semanticscholar   +1 more source

Association of Abatacept With Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis–Associated Interstitial Lung Disease: An Emulated Target Trial

Arthritis &Rheumatology, EarlyView.
Objective The optimal treatment strategy for rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) remains uncertain, and direct comparative data between biologics are limited. This study aimed to evaluate the effectiveness and safety of abatacept compared with rituximab in patients with RA‐ILD.
Po‐Cheng Shih, Shiow‐Ing Wang, Qing‐Wen Wang, James Cheng Chung Wei   +3 more
wiley   +1 more source